SLC2A5 and acute lymphoblastic leukemia: Zhao et al. showed that increased SLC2A5 (GLUT5) expression in pediatric Ph+ALL correlates with disease relapse and treatment resistance, and notably, tyrosine kinase inhibitors reduce GLUT5 expression, thereby decreasing fructose uptake 134.